Recursion Pharmaceuticals stock reached a key performance benchmark, with its Relative Strength (RS) Rating rising into the ...

Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse ...

Shares of Recursion Pharmaceuticals closed 23.88% higher on Friday, marking their best single-day gain in nearly two years.

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in ...

EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...